Pennie & Edmonds LLP
RNase L activators and antisense oligonucleotides effective to treat RSV infections
 The invention concerns a compounds and methods for treating infection with Respiratory Syncytial Virus. The compounds comprise an antisense portion, which is complementary to a normally single stranded portion of the RSV antigenomic strand (the mRNA strand), a linker and a oligonucleotide activator of RNase L, a ubiquitous non-specific RNase. The method comprised forming a complex of an activated RNase L and the antisense molecule. The application teaches methods of determining which portions of the RSV antigenomic strand are normally single-stranded. The application teaches that an antisense oligonucleotide having the sequence of residues 8281-8299 of the RSV genome is particularly useful to practice the invention and provides in vitro results superior to those obtainable with the conventional drug of choice, ribavirin. 
The Cleveland Clinic Fouindation and Government
A C C A A A C C
A61P C07H C12N A61P A61K A61K C12N C12N
inventional inventional additional inventional additional inventional additional inventional
Paul F. Robert Hugh Wei Guiying Nick Mario
Torrence Silverman Xiao Li Cirino